Plus Therapeutics Ownership
| PSTV Stock | USD 1.28 0.05 4.07% |
Shares in Circulation | First Issued 2001-03-31 | Previous Quarter 10.7 M | Current Value 7.9 M | Avarage Shares Outstanding 498.5 K | Quarterly Volatility 1.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Plus |
Plus Stock Ownership Analysis
The company recorded a loss per share of 2.37. Plus Therapeutics last dividend was issued on the 6th of August 2019. The entity had 1:15 split on the 1st of May 2023. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Plus Therapeutics contact MD MBA at 737 255 7194 or learn more at https://plustherapeutics.com.Besides selling stocks to institutional investors, Plus Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Plus Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Plus Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Plus Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Roughly 2.0% of Plus Therapeutics are currently held by insiders. Unlike Plus Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Plus Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Plus Therapeutics' insider trades
Plus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Plus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Plus Therapeutics backward and forwards among themselves. Plus Therapeutics' institutional investor refers to the entity that pools money to purchase Plus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Aigh Capital Management, Llc | 2024-09-30 | 560.9 K | Geode Capital Management, Llc | 2024-09-30 | 54.3 K | Vanguard Group Inc | 2024-09-30 | 32.5 K | Blackrock Inc | 2024-06-30 | 7 K | Tower Research Capital Llc | 2024-06-30 | 4.2 K | Ubs Group Ag | 2024-06-30 | 3.2 K | Advisor Group Holdings, Inc. | 2024-06-30 | 133 | Jpmorgan Chase & Co | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 47.0 |
Plus Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Plus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Plus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Plus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Plus Therapeutics Outstanding Bonds
Plus Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Plus Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Plus bonds can be classified according to their maturity, which is the date when Plus Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.